Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?
Medscape,
Hello. I'm Dr Charles Vega, and I am a clinical professor of family medicine at the University of California at Irvine.
Hello. I'm Dr Charles Vega, and I am a clinical professor of family medicine at the University of California at Irvine.
SGLT2 inhibitors were first approved in 2013 for the treatment of type 2 diabetes.
NEW ORLEANS – Dapagliflozin markedly reduces the risks of both major adverse cardiovascular events and heart failure…
NEW ORLEANS – Dapagliflozin markedly reduces the risks of both major adverse cardiovascular events and heart failure…
The analyses carving up the data according to prior MI and baseline EF are provocative and warrant the attention of…
The analyses carving up the data according to prior MI and baseline EF are provocative and warrant the attention of…
More than a decade after an FDA mandate for cardiovascular outcomes trials, cardiologists say insights gained on how 2 new drug…
More than a decade after an FDA mandate for cardiovascular outcomes trials, cardiologists say insights gained on how 2 new drug…
The ACC's 2018 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2…
Hello. I'm Dr Charles Vega, and I am a clinical professor of family medicine at the University of California at Irvine.
An expert consensus decision pathway recently published by the American College of Cardiology highlights studies that show…
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, William T Cefalu, James L Januzzi, Rita Rastogi Kalyani…
The 2008 decision to mandate large-scale clinical cardiovascular trials transformed the treatment of diabetes for millions of…
For the past 100 years, diabetes has been regarded primarily as a disorder of blood glucose.
Here are what the editors at HealthDay consider to be the most important developments in Cardiology for November 2018.
Here are what the editors at HealthDay consider to be the most important developments in Psychiatry for November 2018.
Here are what the editors at HealthDay consider to be the most important developments in Hematology
The American College of Cardiology (ACC) published a new expert consensus statement in the Journal of the American College of…
Here are what the editors at HealthDay consider to be the most important developments in Cardiology for November 2018.
Sandeep R. Das, M.D., M.P.H., from UT Southwestern Medical Center in Texas, and colleagues provide guidance on use of glucose-low…
(HealthDay News) — Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1…
THURSDAY, Nov. 29, 2018 (HealthDay News) -- Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide…
The authors noted that until recently, medications to control blood glucose were not expected to offer any benefit in helping…
| Journal Certain sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate…
– Allison Inserro November 28, 2018 – Jackie Syrop November 28, 2018 – Laura Joszt November 28, 2018 – AJMC Staff November 27…
THURSDAY, Nov. 29, 2018 -- Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor…
The American College of Cardiology has issued an Expert Consensus Decision Pathway aimed at educating cardiologists on the use…
The American College of Cardiology (ACC) published a new expert consensus statement in the Journal of the American College of…